Acromegaly patients in the non-randomized no OAD and OAD groups maintained mean HbA1c < 6.5% and FPG < 126 mg/dL with pasireotide treatment, whereas in the insulin at entry group, mean HbA1c and FPG levels were elevated at baseline and remained > 6.5% and > 126 mg/dL, respectively, over time (Fig. 3C and D). Here, INS is linked to acromegaly.